A chondrosarcoma (disease) that involves the bone tissue.
Comprehensive, easy-to-understand information about this condition
How we create this content →Documentation about bone chondrosarcoma is limited due to its rarity, affecting fewer than 1 in 100,000 people globally. This rarity results in a lack of systematic clinical studies and comprehensive data on its clinical features and genetic basis. Additionally, the overlap of symptoms with other bone tumors complicates accurate characterization and understanding of the disease.
To effectively manage bone chondrosarcoma, it is essential to seek care from an oncologist who specializes in sarcomas, particularly those with experience in bone tumors. You may also benefit from connecting with a genetic counselor, especially if there are concerns about hereditary factors. For additional resources, consider visiting the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov. Participating in clinical trials may also provide access to cutting-edge treatments, so inquire about eligibility during your consultations.
Currently, there are three orphan drugs designated for bone chondrosarcoma: angiotensin 1-7, ivosidenib, and a Tetravalent recombinant humanized IgG1 agonist antibody targeting the human TRAIL death receptor 5 (DR5). There are also 15 active clinical trials investigating various treatment options. For more information on these trials, you can visit ClinicalTrials.gov and search for 'bone chondrosarcoma'.
Actionable guidance for navigating care for bone chondrosarcoma
To effectively manage bone chondrosarcoma, it is essential to seek care from an oncologist who specializes in sarcomas, particularly those with experience in bone tumors. You may also benefit from connecting with a genetic counselor, especially if there are concerns about hereditary factors. For additional resources, consider visiting the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov. Participating in clinical trials may also provide access to cutting-edge treatments, so inquire about eligibility during your consultations.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation about bone chondrosarcoma is limited due to its rarity, affecting fewer than 1 in 100,000 people globally. This rarity results in a lack of systematic clinical studies and comprehensive data on its clinical features and genetic basis. Additionally, the overlap of symptoms with other bone tumors complicates accurate characterization and understanding of the disease.
To effectively manage bone chondrosarcoma, it is essential to seek care from an oncologist who specializes in sarcomas, particularly those with experience in bone tumors. You may also benefit from connecting with a genetic counselor, especially if there are concerns about hereditary factors. For additional resources, consider visiting the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov. Participating in clinical trials may also provide access to cutting-edge treatments, so inquire about eligibility during your consultations.
Currently, there are three orphan drugs designated for bone chondrosarcoma: angiotensin 1-7, ivosidenib, and a Tetravalent recombinant humanized IgG1 agonist antibody targeting the human TRAIL death receptor 5 (DR5). There are also 15 active clinical trials investigating various treatment options. For more information on these trials, you can visit ClinicalTrials.gov and search for 'bone chondrosarcoma'.
Actionable guidance for navigating care for bone chondrosarcoma
To effectively manage bone chondrosarcoma, it is essential to seek care from an oncologist who specializes in sarcomas, particularly those with experience in bone tumors. You may also benefit from connecting with a genetic counselor, especially if there are concerns about hereditary factors. For additional resources, consider visiting the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov. Participating in clinical trials may also provide access to cutting-edge treatments, so inquire about eligibility during your consultations.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation about bone chondrosarcoma is limited due to its rarity, affecting fewer than 1 in 100,000 people globally. This rarity results in a lack of systematic clinical studies and comprehensive data on its clinical features and genetic basis. Additionally, the overlap of symptoms with other bone tumors complicates accurate characterization and understanding of the disease.
To effectively manage bone chondrosarcoma, it is essential to seek care from an oncologist who specializes in sarcomas, particularly those with experience in bone tumors. You may also benefit from connecting with a genetic counselor, especially if there are concerns about hereditary factors. For additional resources, consider visiting the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov. Participating in clinical trials may also provide access to cutting-edge treatments, so inquire about eligibility during your consultations.
Currently, there are three orphan drugs designated for bone chondrosarcoma: angiotensin 1-7, ivosidenib, and a Tetravalent recombinant humanized IgG1 agonist antibody targeting the human TRAIL death receptor 5 (DR5). There are also 15 active clinical trials investigating various treatment options. For more information on these trials, you can visit ClinicalTrials.gov and search for 'bone chondrosarcoma'.
Actionable guidance for navigating care for bone chondrosarcoma
To effectively manage bone chondrosarcoma, it is essential to seek care from an oncologist who specializes in sarcomas, particularly those with experience in bone tumors. You may also benefit from connecting with a genetic counselor, especially if there are concerns about hereditary factors. For additional resources, consider visiting the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov. Participating in clinical trials may also provide access to cutting-edge treatments, so inquire about eligibility during your consultations.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.